A

AlloVir
D

ALVR

9.30000
USD
-0.54
(-5.49%)
مغلق
حجم التداول
208
الربح لكل سهم
0
العائد الربحي
-
P/E
-0
حجم السوق
46,889,968
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AAPL
    AAPL
    -0.310
    (-0.13%)
    245.560 USD
    AMZN
    AMZN
    -6.305
    (-2.83%)
    216.495 USD
    GOOGL
    GOOGL
    -4.895
    (-2.65%)
    179.685 USD
    MSFT
    MSFT
    -7.96
    (-1.91%)
    408.15 USD
    NVDA
    NVDA
    -5.850
    (-4.18%)
    134.260 USD
    S
    SNAP
    -0.330
    (-3.09%)
    10.345 USD
    TSLA
    TSLA
    -16.87
    (-4.76%)
    337.50 USD
    ZM
    ZM
    -0.930
    (-1.11%)
    82.510 USD
    المزيد
الأخبار
المقالات

العنوان: AlloVir Inc

القطاع: Healthcare
الصناعة: Biotechnology
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.